Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ardelyx, Inc. (NASDAQ: ARDX) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Ardelyx securities between January 13, 2025, and August 6, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case.

Ardelyx Case Details

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that:

  1. Ardelyx was experiencing increasing payer-related access and reimbursement barriers affecting patient access to XPHOZAH and IBSRELA;
  2. more stringent prior authorization and step-edit requirements were slowing new-patient starts and delaying prescription fulfillment;
  3. these payer utilization-management processes were negatively impacting Ardelyx’s commercial performance and growth prospects for XPHOZAH and IBSRELA;
  4. as a result, Defendants overstated Ardelyx’s commercial performance and growth prospects for XPHOZAH and IBSRELA; and
  5. as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

What’s Next for Ardelyx Investors?

A class action lawsuit has already been filed. You may review a copy of the Complaint. You may also contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911. If you suffered a loss in Ardelyx you have until November 16, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.